Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
CONTEXT: Pituitary effects of long-term therapy with mifepristone, a glucocorticoid receptor antagonist, in Cushing's disease (CD) patients are not well understood. OBJECTIVE: Our objective was to report changes in ACTH and pituitary magnetic resonance imaging (MRI) findings during long-term use of mifepristone in CD patients. DESIGN AND SETTING: The Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing's Syndrome (SEISMIC) was a 24-week, open-label study of mifepristone, and its long-term extension (LTE) is a multicenter U.S. study. PATIENTS: Forty-three CD patients (mean age 45.3 years) were enrolled in SEISMIC with 27 continuing into the LTE study. INTERVENTIONS: Mifepristone (300-1200 mg) was administered once daily. MAIN OUTCOME MEASURES: ACTH and pituitary MRI were assessed at baseline and at regular intervals during treatment. RESULTS: A ≥2-fold increase in ACTH was observed in 72% of patients treated for a median duration of 11.3 months. The mean peak increase in ACTH was 2.76 ± 1.65-fold during SEISMIC, and mean ACTH concentrations remained stable during the LTE. ACTH was directly correlated with mifepristone dose and declined to near baseline levels after mifepristone discontinuation. Tumor regressed in 2 patients and progressed in 3 patients with macroadenomas. An additional microadenoma was identified after 25 months of treatment after a baseline tumor-negative MRI. CONCLUSIONS: In the largest prospective study to date, long-term mifepristone treatment increased ACTH in approximately two-thirds of patients with CD. ACTH elevations were observed within the first few weeks of treatment, were dose-dependent, and generally remained stable over time. Corticotroph tumor progression and regression may occur over time, but patients may have significant increases in ACTH levels without evidence of tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Self-citationFleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479 · cited 6×
“8% of the 43 patients with CD experienced at least a 2-fold increase in ACTH (21).”
BackgroundMethodResultInfluentialSelf-citationMultisystem morbidity and mortality in Cushing’s syndrome: a cohort study
Dekkers, O. M., Horváth-Puhó, E., Jørgensen, J. O. L., Cannegieter, S. C., Ehrenstein, V., Vandenbroucke, J. P., Pereira, A. M., & Sørensen, H. T. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3582 · Cited by 419 · cited 1×
“Cushing’s disease (CD) is a serious condition of chronic hypercortisolism caused by an ACTH-secreting pituitary tumor and is associated with increased morbidity and mortality (1, 2).”
BackgroundGonadal steroid hormones and the hypothalamo–pituitary–adrenal axis
Handa, R. J., & Weiser, M. J. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.11.001 · Cited by 408
Verhelst, J. A., Trainer, P. J., Howlett, T. A., Perry, L., Rees, L. H., Grossman, A. B., Wass, J. A. H., & Sesser, G. M. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03517.x · Cited by 308 · cited 1×
“Drugs that reduce cortisol levels such as metyrapone and mitotane have been associated with increases in ACTH (11, 12); interestingly, ACTH increases may be less commonly observed in patients treated with ketoconazole possibly due to an independent effect on ACTH inhibition (13, 14).”
BackgroundKetoconazole treatment in Cushing’s syndrome: experience in 34 patients
Sonino, N., Boscaro, M., Paoletta, A., Mantero, F., & Zillotto, D. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03547.x · Cited by 201 · cited 1×
“Drugs that reduce cortisol levels such as metyrapone and mitotane have been associated with increases in ACTH (11, 12); interestingly, ACTH increases may be less commonly observed in patients treated with ketoconazole possibly due to an independent effect on ACTH inhibition (13, 14).”
BackgroundEfficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187 · cited 4×
“Corticotroph tumor progression has been demonstrated after medical treatment (12, 20) and BLA (7, 16, 43).”
BackgroundInfluentialKino, T., Su, Y. A., & Chrousos, G. P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0098-z · Cited by 179
Human Glucocorticoid Receptor β Binds RU-486 and Is TranscriptionallyActive
Lewis-Tuffin, L. J., Jewell, C. M., Bienstock, R. J., Collins, J. B., & Cidlowski, J. A. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01439-06 · Cited by 175 · cited 1×
“Instead, it causes conformational changes in GR that modulate receptor dimerization, corepressor/activator interaction, DNA binding, and transcription (48–50) and modulates gene expression in distinct ways (51, 52).”
BackgroundKetoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease
Castinetti, F., Morange, I., Jaquet, P., Conte-Devolx, B., & Brue, T. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0514 · Cited by 175
Cited by
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Self-citationConsensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Cushing's disease: pathobiology, diagnosis, and management
Lonser, R. R., Nieman, L., & Oldfield, E. H. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152119 · Cited by 215
Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143
Metadata
- Authors
- Fleseriu, M., Findling, J. W., Koch, C. A., Schlaffer, S.-M., Buchfelder, M., & Gross, C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-10
- Volume
- 99
- Issue
- 10
- Pages
- 3718-3727
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2160912499
- Cited by
- 86
- References
- 11
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone. https://app.cochat.ai/papers/10.1210/jc.2014-1843
- The paper
- Fleseriu, M., Findling, J. W., Koch, C. A., Schlaffer, S.-M., Buchfelder, M., & Gross, C. (2014). Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2014-1843
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.